|
1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
|
2
|
Lang H, Sotiropoulos GC, Brokalaki EI,
Schmitz KJ, Bertona C, Meyer G, Frilling A, Paul A, Malagó M and
Broelsch CE: Survival and recurrence rates after resection for
hepatocellular carcinoma in noncirrhotic livers. J Am Coll Surg.
205:27–36. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gish RG and Baron A: Hepatocellular
carcinoma (HCC): current and evolving therapies. IDrugs.
11:198–203. 2008.PubMed/NCBI
|
|
4
|
Gordaliza M: Natural products as leads to
anticancer drugs. Clin Transl Oncol. 9:767–776. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jia L: Cancer complementary and
alternative medicine research at the US National Cancer Institute.
Chin J Integr Med. 18:325–332. 2012. View Article : Google Scholar
|
|
6
|
Carmady B and Smith CA: Use of Chinese
medicine by cancer patients: a review of surveys. Chin Med.
9:222011. View Article : Google Scholar
|
|
7
|
Cheueng S and Tai J: In vitro
studies of the dry fruit of Chinese fan palm Livistona
chinensis. Oncol Rep. 5:1331–1336. 2005.
|
|
8
|
Sartippour MR, Liu C and Shao ZM:
Livistona extract inhibits angiogenesis and cancer growth.
Oncol Rep. 6:1355–1357. 2001.
|
|
9
|
Huang WC, Hsu RM, Chi LM, et al: Selective
downregulation of EGF receptor and downstream MAPK pathway in human
cancer cell lines by active components partially purified from the
seeds of Livistona chinensis R. Brown. Cancer Lett.
248:137–146. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang H, Li A, Dong XP and Xu XY: Screening
of anti-tumor parts from the seeds of Livistona chinensis
and its anti-angiogenesis effect. Zhong Yao Cai. 31:718–722.
2008.(In Chinese).
|
|
11
|
Lin W, Zhao J, Cao Z, Zhuang Q, Zheng L,
Cai Q, Chen D, Wang L, Hong Z and Peng J: Livistona
chinensis seed suppresses hepatocellular carcinoma growth
through promotion of mitochondrial-dependent apoptosis. Oncol Rep.
29:1859–1866. 2013.
|
|
12
|
Folkman J and Klagsbrun M: Angiogenic
factors. Science. 235:442–447. 1987. View Article : Google Scholar
|
|
13
|
Folkman J: Tumor angiogenesis: therapeutic
implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Schneider BP and Miller KD: Angiogenesis
of breast cancer. J Clin Oncol. 23:1782–1790. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Uzzan B, Nicolas P, Cucherat M and Perret
GY: Microvessel density as a prognostic factor in women with breast
cancer: a systematic review of the literature and meta-analysis.
Cancer Res. 64:2941–2955. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Weidner N: The importance of tumor
angiogenesis: the evidence continues to grow. Am J Clin Pathol.
122:675–677. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kut C, Mac Gabhann F and Popel AS: Where
is VEGF in the body? A meta-analysis of VEGF distribution in
cancer. Br J Cancer. 97:978–985. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Takeshita K, Satoh M, Ii M, Silver M,
Limbourg FP, Mukai Y, Rikitake Y, Radtke F, Gridley T, Losordo DW
and Liao JK: Critical role of endothelial Notch1 signaling in
postnatal angiogenesis. Circ Res. 100:70–78. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Garcia A and Kandel JJ: Notch: a key
regulator of tumor angiogenesis and metastasis. Histol Histopathol.
27:151–156. 2012.PubMed/NCBI
|
|
20
|
Dufraine J, Funahashi Y and Kitajewski J:
Notch signaling regulates tumor angiogenesis by diverse mechanisms.
Oncogene. 27:5132–5137. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ridgway J, Zhang G, Wu Y, Stawicki S,
Liang WC, Chanthery Y, Kowalski J, Watts RJ, Callahan C, Kasman I,
Singh M, Chien M, Tan C, Hongo JA, de Sauvage F, Plowman G and Yan
M: Inhibition of Dll4 signalling inhibits tumour growth by
deregulating angiogenesis. Nature. 444:1083–1087. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Miele L, Golde T and Osborne B: Notch
signaling in cancer. Curr Mol Med. 6:905–918. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yanagawa S, Lee JS, Kakimi K, Matsuda Y,
Honjo T and Ishimoto A: Identification of Notch1 as a
frequent target for provirus insertional mutagenesis in T-cell
lymphomas induced by leukemogenic mutants of mouse mammary tumor
virus. J Virol. 74:9786–9791. 2000.
|
|
24
|
Ellisen LW, Bird J, West DC, Soreng AL,
Reynolds TC, Smith SD and Sklar J: TAN-1, the human homolog
of the Drosophila Notch gene, is broken by chromosomal
translocations in T lymphoblastic neoplasms. Cell. 66:649–661.
1991. View Article : Google Scholar
|
|
25
|
Sjölund J, Manetopoulos C, Stockhausen MT
and Axelson H: The Notch pathway in cancer: differentiation gone
awry. Eur J Cancer. 41:2620–2629. 2005.PubMed/NCBI
|
|
26
|
Nijjar SS, Crosby HA, Wallace L, Hubscher
SG and Strain AJ: Notch receptor expression in adult human liver: a
possible role in bile duct formation and hepatic
neovascularization. Hepatology. 34:1184–1192. 2001. View Article : Google Scholar
|
|
27
|
Nijjar SS, Wallace L, Crosby HA, Hubscher
SG and Strain AJ: Altered Notch ligand expression in human liver
disease: further evidence for a role of the Notch signaling pathway
in hepatic neovascularization and biliary ductular defects. Am J
Pathol. 160:1695–1703. 2002. View Article : Google Scholar
|
|
28
|
Dorrell MI, Aguilar E, Scheppke L, Barnett
FH and Friedlander M: Combination angiostatic therapy completely
inhibits ocular and tumor angiogenesis. Proc Natl Acad Sci USA.
104:967–972. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Folkman J and Shing Y: Angiogenesis. J
Biol Chem. 267:10931–10934. 1992.
|
|
30
|
Folkman J: Angiogenesis in cancer,
vascular, rheumatoid and other disease. Nat Med. 1:27–31. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Folkman J: Angiogenesis. Annu Rev Med.
57:1–18. 2006. View Article : Google Scholar
|
|
32
|
Weidner N, Semple JP, Welch WR and Folkman
J: Tumor angiogenesis and metastasis - correlation in invasive
breast carcinoma. N Engl J Med. 324:1–8. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Risau W: Mechanisms of angiogenesis.
Nature. 386:671–674. 1997. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jain RK: Tumor angiogenesis and
accessibility: role of vascular endothelial growth factor. Semin
Oncol. 29(Suppl 16): 3–9. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ferrara N: Role of vascular endothelial
growth factor in physiologic and pathologic angiogenesis:
therapeutic implications. Semin Oncol. 29(Suppl 16): 10–14. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Maeda K, Chung YS, Ogawa Y, Takatsuka S,
Kang SM, Ogawa M, Sawada T and Sowa M: Prognostic value of vascular
endothelial growth factor expression in gastric carcinoma. Cancer.
77:858–863. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kaya M, Wada T, Akatsuka T, Kawaguchi S,
Nagoya S, Shindoh M, Higashino F, Mezawa F, Okada F and Ishii S:
Vascular endothelial growth factor expression in untreated
osteosarcoma is predictive of pulmonary metastasis and poor
prognosis. Clin Cancer Res. 6:572–577. 2000.PubMed/NCBI
|
|
38
|
Ferrara N, Gerber HP and LeCouter J: The
biology of VEGF and its receptors. Nat Med. 9:669–676. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Purow B: Notch inhibition as a promising
new approach to cancer therapy. Adv Exp Med Biol. 727:305–319.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Gale NW, Dominguez MG, Noguera I, Pan L,
Hughes V, Valenzuela DM, Murphy AJ, Adams NC, Lin HC, Holash J,
Thurston G and Yancopoulos GD: Haploinsufficiency of delta-like 4
ligand results in embryonic lethality due to major defects in
arterial and vascular development. Proc Natl Acad Sci USA.
101:15949–15954. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Duarte A, Hirashima M, Benedito R,
Trindade A, Diniz P, Bekman E, Costa L, Henrique D and Rossant J:
Dosage-sensitive requirement for mouse Dll4 in artery development.
Genes Dev. 18:2474–2478. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Skrtic A, Sokolic L, Borovecki A, Rosa J
and Fenzl V: Immunohistochemical localization of CD31, NOTCH1 and
JAGGED1 proteins in experimentally induced polycystic ovaries of
immature rats. Acta Histochem. 113:262–269. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Benedito R, Roca C, Sörensen I, Adams S,
Gossler A, Fruttiger M and Adams RH: The notch ligands Dll4 and
Jagged1 have opposing effects on angiogenesis. Cell. 137:1124–1135.
2009. View Article : Google Scholar : PubMed/NCBI
|
